🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK573719 125mcg

Found 16 matching trials

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

PHASE1

This study will assess the safety and pharmacokinetics of inhaled GSK573719...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-03-29

Trial ID

NCT01571999

Treatments Being Tested

Inhaled GSK573719 Inhaled GSK573719/vilanterol

28-day Repeat Dose Study of GSK573719

PHASE2

The study will evaluate the efficacy, safety, and pharmacokinetics of GSK57...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-12-15

Trial ID

NCT01030965

Treatments Being Tested

GSK573719 125mcg GSK573719 250mcg GSK573719 500mcg Placebo

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01328444

Treatments Being Tested

GSK 573719 +GW642444 125/25 GSK573719 + GW642444 62.5/25 GSK 573719 125 GSK 573719 62.5 GW642444 25 Plb

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

PHASE3

After screening, subjects will enter a 4 week open-label run-in period with...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-10

Trial ID

NCT02119286

Treatments Being Tested

FF VI UMEC Placebo

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-16

Trial ID

NCT01323660

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GSK573719 125 GSK573719 62.5 GW642444 25 placebo

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

PHASE2

The study will evaluate the dose response, safety, and pharmacokinetics of ...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-09-01

Trial ID

NCT00950807

Treatments Being Tested

Tiotropium Placebo GSK573179

Long-term Safety Study for GSK573719 in Japanese

PHASE3

The objective of this study is to evaluate the safety and tolerability of G...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-08

Trial ID

NCT01702363

Treatments Being Tested

GSK573719

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this 52-week study is to evaluate the long-term safety (in t...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-01-01

Trial ID

NCT01316887

Treatments Being Tested

125/25 mcg once-daily GSK573719/GW642444 125mcg once-daily GSK573719 Placebo once-daily

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

PHASE2

This is a multi-national, randomized, double-blind, 3-period crossover, inc...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-05

Trial ID

NCT01641692

Treatments Being Tested

GSK573719 Active treatment or Placebo GSK573719 (Sub-group cohort)Salbutamol/Albuterol

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

PHASE3

The purpose of this 12 week study is to evaluate the effects of the additio...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-01

Trial ID

NCT01772147

Treatments Being Tested

Umeclidinium bromide 62.5mcg Umeclidinium bromide 125mcg Fluticasone propionate 250mcg/Salmeterol 50mcg

Previous Next